Zobrazeno 1 - 10
of 97
pro vyhledávání: '"Shinichiro SUZUKI"'
Autor:
Takashi Kurosaki, Kenji Chamoto, Shinichiro Suzuki, Hiroaki Kanemura, Seiichiro Mitani, Kaoru Tanaka, Hisato Kawakami, Yo Kishimoto, Yasuharu Haku, Katsuhiro Ito, Toshiyuki Sato, Chihiro Suminaka, Mami Yamaki, Yasutaka Chiba, Tomonori Yaguchi, Koichi Omori, Takashi Kobayashi, Kazuhiko Nakagawa, Tasuku Honjo, Hidetoshi Hayashi
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionThe clinical relevance of soluble forms of programmed cell death-1 (sPD-1) and programmed cell death-ligand 1 (sPD-L1) remains unclear. We here investigated the relation between the efficacy of PD-1 blockade and pretreatment plasma levels
Externí odkaz:
https://doaj.org/article/ca0552f7ccdf42e3ad9e80f1d87a4c8b
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-6 (2022)
Abstract Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used for their antipyretic, analgesic, and anti-inflammatory properties. However, various aspects of NSAID-induced lower gastrointestinal tract injury remain unclear, and effective pr
Externí odkaz:
https://doaj.org/article/1f4febe98c454145b5f7ddb43ca1c7e6
Autor:
Shinsuke Suzuki, Teni Godai, Shin Kato, Atsushi Onodera, Kazuya Endo, Shizune Onuma, Yui Honjo, Junya Shirai, Masakatsu Numata, Yutaka Kumakiri, Shinichiro Suzuki, Yuji Yamamoto
Publikováno v:
Journal of the Anus, Rectum and Colon, Vol 6, Iss 1, Pp 72-76 (2022)
We describe our experience with robotic posterior rectopexy for a patient with full-thickness rectal prolapse. To our knowledge, this is the first report of such a case in the literature. A 94-year-old woman presented with a history of gradually wors
Externí odkaz:
https://doaj.org/article/0e91ea1e138641dea0c34e79431a4461
Autor:
Hiroaki Kanemura, MD, MPH, Hidetoshi Hayashi, MD, PhD, Shuta Tomida, PhD, Junko Tanizaki, MD, PhD, Shinichiro Suzuki, MD, PhD, Yusuke Kawanaka, MD, Asuka Tsuya, MD, Yasushi Fukuda, MD, Hiroyasu Kaneda, MD, PhD, Keita Kudo, MD, Takayuki Takahama, MD, PhD, Ryosuke Imai, MD, Koji Haratani, MD, PhD, Yasutaka Chiba, PhD, Tomoyuki Otani, MD, Akihiko Ito, MD, PhD, Kazuko Sakai, PhD, Kazuto Nishio, MD, PhD, Kazuhiko Nakagawa, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 8, Pp 100373- (2022)
Introduction: Despite a considerable benefit of adding immune checkpoint inhibitors (ICIs) to platinum-based chemotherapy for patients with extensive-stage SCLC (ES-SCLC), a durable response to ICIs occurs in only a small minority of such patients. M
Externí odkaz:
https://doaj.org/article/dbb20eead9094769a8713112200e34c2
Autor:
Kanade HOKARI, Shinichiro SUZUKI, Naoki OKAMOTO, Takeyasu SAITO, Isamu IDE, Masanobu NISHIKAWA, Yoshikazu ONISHI
Publikováno v:
Electrochemistry, Vol 88, Iss 3, Pp 127-131 (2020)
Active carbon was prepared by treating carburized furfural resin particles (1 µm in diameter) with potassium hydroxide solution for 0–0.5 h at 700–800°C in flowing nitrogen gas. The pore structure of the active carbon was then evaluated by nitr
Externí odkaz:
https://doaj.org/article/e9aab01d0874423191e7543e988b073a
Autor:
Seiichiro Mitani, Hisato Kawakami, Osamu Shiraishi, Hiroaki Kanemura, Shinichiro Suzuki, Koji Haratani, Hidetoshi Hayashi, Kimio Yonesaka, Yasutaka Chiba, Takushi Yasuda, Kazuhiko Nakagawa
Publikováno v:
Esophagus. 20:281-289
Neoadjuvant docetaxel plus cisplatin and 5-FU (NAC-DCF) and adjuvant nivolumab monotherapy are the standard care for locally advanced resectable esophageal squamous cell carcinoma (ESCC). However, no effective biomarkers have been found in perioperat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de00b1e6304f6b4a0519fd989551d32c
https://doi.org/10.1007/s10388-022-00976-9
https://doi.org/10.1007/s10388-022-00976-9
Autor:
Kazuhiko Nakagawa, Kazuto Nishio, Kazuko Sakai, Hidetoshi Hayashi, Hisato Kawakami, Junko Tanizaki, Koji Haratani, Hitomi Sakai, Ryoji Kato, Toshiyuki Takehara, Takeshi Teramura, Kimio Yonesaka, Shinichiro Suzuki
Purpose:Treatment with KRASG12C inhibitors such as sotorasib can produce substantial regression of tumors in some patients with non–small cell lung cancer (NSCLC). These patients require alternative treatment after acquiring resistance to the inhib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::515508c588c2e1caeb4109c863e2de8b
https://doi.org/10.1158/1078-0432.c.6530453.v1
https://doi.org/10.1158/1078-0432.c.6530453.v1
Autor:
Toshiyuki Takehara, Kimio Yonesaka, Hitomi Sakai, Koji Haratani, Hidetoshi Hayashi, Kazuko Sakai, Hisato Kawakami, Kazuhiko Nakagawa, Takeshi Teramura, Shinichiro Suzuki, Kazuto Nishio, Ryoji Kato, Junko Tanizaki
Publikováno v:
Clinical Cancer Research. 27:5697-5707
Purpose: Treatment with KRASG12C inhibitors such as sotorasib can produce substantial regression of tumors in some patients with non–small cell lung cancer (NSCLC). These patients require alternative treatment after acquiring resistance to the inhi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9388875a02674208e3868a97c2eb6a7d
https://doi.org/10.1158/1078-0432.ccr-21-0856
https://doi.org/10.1158/1078-0432.ccr-21-0856
Autor:
Masayuki Takeda, Kazuto Nishio, Takayuki Takahama, Hidetoshi Hayashi, Kazuko Sakai, Takeshi Yoshida, Kazuhiko Nakagawa, Shinichiro Suzuki, Hiroyasu Kaneda, Kaoru Tanaka, Ryoji Kato, Koji Haratani, Yoshikane Nonagase, Junko Tanizaki, Kimio Yonesaka
Publikováno v:
International Journal of Clinical Oncology. 26:1628-1639
We here applied cancer personalized profiling by deep sequencing (CAPP-seq) to analysis of circulating tumor DNA (ctDNA) to identify resistance mechanisms in osimertinib-treated patients with EGFR T790M–positive non–small cell lung cancer (NSCLC)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::562794cc8c9d34594c0ba9652fbf8f1c
https://doi.org/10.1007/s10147-021-01947-3
https://doi.org/10.1007/s10147-021-01947-3
Autor:
Shinichiro Suzuki, Kazuya Fukuoka, Hisato Kawakami, Soichi Fumita, Kazuhiko Nakagawa, Hidetoshi Hayashi, Chihiro Sato, Kazuko Sakai, Shigeki Shimizu, Tatsuya Okuno, Koji Haratani, Akihiko Ito, Yoshikane Nonagase, Kazumasa Saigoh, Kimio Yonesaka, Hisashi Handa, Takeshi Yoshida, Masayuki Takeda, Tetsuya Mitsudomi, Kazuto Nishio, Takayuki Takahama, Naoki Takegawa, Satomi Watanabe, Kaoru Tanaka
Publikováno v:
The Oncologist
Background Implementation of personalized medicine requires the accessibility of tumor molecular profiling in order to allow prioritization of appropriate targeted therapies for individual patients. Our aim was to study the role of comprehensive geno
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc318dce87b8526689c6b4d1f95fe532
http://europepmc.org/articles/PMC8018334
http://europepmc.org/articles/PMC8018334